HLT Megathread on HMI-115 (key takeaways in comments) Research/Science 1/23/2023
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
View this post in the Community →
Similar Community Posts Join
5 / 141 resultscommunity hmi115 is coming. Prepare yourselves for what's coming
The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.
community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
community Does CosmeRNA target the root cause of MPB?
.
CumsOnYourFeet69 has been discussing a new treatment called CosmeRNA which claims to target the root cause of male pattern baldness, and is considering using it in conjunction with Minoxidil instead of Finasteride due to possible side effects. Replies have highlighted that the efficacy of this treatment is still unknown, but it could be used as an effective maintenance option if successful.
community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
community Prolactin’s role in antitumor activity of the immune system – a safety concern for HMI-115?
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.
Related Research
6 / 45 results
research Recent Approaches of Antibody Therapeutics in Androgenetic Alopecia
Antibody treatments show promise for hair loss but need more research.
research The Pathophysiology of Polycystic Ovary Syndrome: Understanding PCOS and Its Endocrinology
The conclusion is that PCOS is caused by ovarian sensitivity to hormones and disrupted hormone control, possibly due to ovarian factors, and more research is needed.
research The State-of-the-Art in the Management of Androgenetic Alopecia: A Review of New Therapies and Treatment Algorithms
New and existing treatments for hair loss show promise, with some being more effective for men and others for women.
research Topical Application of the Wnt/β-Catenin Activator Methyl Vanillate Increases Hair Count and Hair Mass Index in Women with Androgenetic Alopecia
Methyl vanillate spray increases hair count and hair mass in women with hair loss.
research A Dietary Supplement Improves Age-Related Dermatological Changes: Observational, Anecdotal, Spontaneous Study
The dietary supplement significantly improved skin, nails, and hair in older adults.
research Hypotensive Activity and Toxicology of Constituents from Bombax Ceiba Stem Bark
Bombax ceiba stem bark extracts can lower blood pressure, but high doses can be toxic and lethal.